These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26774017)

  • 41. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?].
    Nauck M; Wilhelm B
    MMW Fortschr Med; 2017 Jun; 159(Suppl 5):7-15. PubMed ID: 28643293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
    Haluzík M; Trachta P; Mráz M
    Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
    Hanefeld M; Raccah D; Monnier L
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The cardiovascular effects of GLP-1 receptor agonists.
    Okerson T; Chilton RJ
    Cardiovasc Ther; 2012 Jun; 30(3):e146-55. PubMed ID: 21167014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
    Lund A; Knop FK; Vilsbøll T
    Eur J Intern Med; 2014 Jun; 25(5):407-14. PubMed ID: 24694879
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.
    Ma X; Liu Z; Ilyas I; Little PJ; Kamato D; Sahebka A; Chen Z; Luo S; Zheng X; Weng J; Xu S
    Int J Biol Sci; 2021; 17(8):2050-2068. PubMed ID: 34131405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes.
    Thomas MC; Coughlan MT; Cooper ME
    Cell Metab; 2023 Feb; 35(2):253-273. PubMed ID: 36754019
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.
    Porcellati F; Lucidi P; Bolli GB; Fanelli CG
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S16-6S20. PubMed ID: 26774015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease.
    Lee HA; Kim HY
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glucagon-like peptide-1 receptor action in the vasculature.
    Almutairi M; Al Batran R; Ussher JR
    Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
    Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GLP-1 as a target for therapeutic intervention.
    Rajeev SP; Wilding J
    Curr Opin Pharmacol; 2016 Dec; 31():44-49. PubMed ID: 27591964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?
    Vergès B; Charbonnel B
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S3-2S12. PubMed ID: 28431669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
    Salvador J; Andrada P
    Med Clin (Barc); 2014; 143 Suppl 2():28-34. PubMed ID: 25326841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incretins and cardiovascular disease: to the heart of type 2 diabetes?
    Solini A; Tricò D; Del Prato S
    Diabetologia; 2023 Oct; 66(10):1820-1831. PubMed ID: 37542009
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.
    Russell-Jones D
    Int J Clin Pract; 2010 Sep; 64(10):1402-14. PubMed ID: 20716148
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.
    Aronson R
    Expert Rev Clin Pharmacol; 2013 Nov; 6(6):603-12. PubMed ID: 24147558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.